11:47 AM EST - Cardiome Pharma Corp. : Announced that the Secretary of State for the U.K. Department of Health has approved pricing for BRINAVESS® (vernakalant hydrochloride). The approved amount represents a maximum price per vial of BRINAVESS® in the United Kingdom. It is consistent with pricing in other territories and Cardiome's economic forecasts. Cardiome Pharma Corp.
shares T.COM are trading up $0.02 at $12.15.
